Risk adjustment models for short-term outcomes after surgical resection for oesophagogastric cancer

Fischer, Claudia; Lingsma, Hester F.; Hardwick, Richard; Cromwell, David; Groene, Oliver

doi:10.1002/bjs.9968

Cited by 31 publications

(22 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, the HES database does not contain data on patient characteristics that could influence their postoperative outcome such as histology, stage of disease, and frailty [22]. The omission of these factors from the risk adjustment model could have reduced its explanatory power, but there is no evidence for these characteristics having changed greatly over study period.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Changes in volume, clinical practice and outcome after reorganisation of oesophago-gastric cancer care in England: A longitudinal observational study

Varagunam

Hardwick

Riley

et al. 2018

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Changes in volume, clinical practice and outcome after reorganisation of oesophago-gastric cancer care in England: A longitudinal observational study

Varagunam

Hardwick

Riley

et al. 2018

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Surgical resection only benefits patients with localized disease and carries a 40% risk of major morbidity and 2–3% risk of perioperative mortality (7, 8). The development of accurate noninvasive imaging markers of EAC would enhance clinical staging by allowing the specific detection of locoregional and distant metastases, enabling treatment stratification (9).…”

mentioning

confidence: 99%

Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins

O’Neill

Pak

Pairo-Castineira

et al. 2017

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Esophageal cancer is the eighth most common cancer worldwide and the majority of patients have systemic disease at presentation. Esophageal adenocarcinoma (OAC), the predominant subtype in western countries, is largely resistant to current chemotherapy regimens. Selective markers are needed to enhance clinical staging and to allow targeted therapies yet there are minimal proteomic data on this cancer type. After histological review, lysates from OAC and matched normal esophageal and gastric samples from seven patients were subjected to LC MS/MS after tandem mass tag labeling and OFFGEL fractionation. Patient matched samples of OAC, normal esophagus, normal stomach, lymph node metastases and uninvolved lymph nodes were used from an additional 115 patients for verification of expression by immunohistochemistry (IHC).Over six thousand proteins were identified and quantified across samples. Quantitative reproducibility was excellent between technical replicates and a moderate correlation was seen across samples with the same histology. The quantitative accuracy was verified across the dynamic range for seven proteins by immunohistochemistry (IHC) on the originating tissues. Multiple novel tumor-specific candidates are proposed and EPCAM was verified by IHC.This shotgun proteomic study of OAC used a comparative quantitative approach to reveal proteins highly expressed in specific tissue types. Novel tumor-specific proteins are proposed and EPCAM was demonstrated to be specifically overexpressed in primary tumors and lymph node metastases compared with surrounding normal tissues. This candidate and others proposed in this study could be developed as tumor-specific targets for novel clinical staging and therapeutic approaches.

show abstract

“…Therefore, although most studies take into consideration the 30-day morbidity/mortality rate, it seems that maybe a more adequate tool in order to quantify the postoperative outcomes is represented by the 90-day morbidity/mortality rate. This fact seems to be true not only in gallbladder cancer patients but also in other malignancies such as pancreatic cancer and esophageal or gastric cancer [41,42].…”

Section: Postoperative Complications After Surgery For Gallbladder Camentioning

confidence: 97%

Surgical Advances in the Treatment of Gallbladder Carcinoma at Different Stages

Bacalbaşa¹,

Bălescu²,

Dima³

et al. 2019

Bile Duct Cancer

View full text Add to dashboard Cite

Gallbladder carcinoma remains the most common cancer originating from the biliary tract, which is associated with poor prognosis and poor survival rates. It is estimated that only one-third of patients with histopathological diagnostic of gallbladder cancer had been correctly diagnosed preoperatively, in the remaining cases the diagnostic being established intraoperatively or postoperatively, based on the histopathological examination. Moreover, although surgery remains the most appropriate therapeutic approach in order to improve survival, it is estimated that only 25% of cases with gallbladder carcinomas present resectable lesions. The current chapter reviews the most appropriate surgical options in patients diagnosed with both early stage and advanced stage gallbladder cancer, by minimally invasive as well as by open approach. In the meantime, the therapeutic strategies in incidentally diagnosed gallbladder cancer will be discussed.

show abstract

Risk adjustment models for short-term outcomes after surgical resection for oesophagogastric cancer

Cited by 31 publications

References 40 publications

Changes in volume, clinical practice and outcome after reorganisation of oesophago-gastric cancer care in England: A longitudinal observational study

Changes in volume, clinical practice and outcome after reorganisation of oesophago-gastric cancer care in England: A longitudinal observational study

Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins

Surgical Advances in the Treatment of Gallbladder Carcinoma at Different Stages

Contact Info

Product

Resources

About